IDEAYA Demonstrates Preclinical Success with PRMT5 Inhibitor IDE892
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a clinical-stage precision medicine oncology company, announced the nomination of IDE892, a potent and selective MTA-cooperative PRMT5 inhibitor, as its latest development candidate. IDE892 is positioned to address unmet needs in MTAP-deleted tumors, leveraging IDEAYA’s synthetic lethality platform.
Topics: Novel Therapeutics